Cytokinetics (CYTK): Transformative VITALITY-ALS Readout on Track - Needham

February 17, 2017 6:58 AM

Needham & Company analyst, Chad Messer, reiterated his Strong Buy rating on shares of Cytokinetics (NASDAQ: CYTK) ahead of a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found